Comparison of the potential for developmental toxicity of prenatal exposure to two dietary chromium supplements, chromium picolinate and [Cr 3O(O2CCH2CH3)6(H 2O)3]+, in mice

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 83, Issue 1, 2008, Pages 27-31

  Bailey, M M ^a   Sturdivant, J ^a   Jernigan, P L ^a   Townsend, M B ^a   Bushman, J ^a   Ankareddi, I ^b   Rasco, J F ^a   Hood, Ronald D ^a,c   Vincent, J B ^a  

^a UNIVERSITY OF ALABAMA   (United States)

^b University of Alabama   (United States)

^c Ronald D Hood and Associates   (United States)

Author keywords

Chromium; Cr3; Developmental toxicity; Fetus; Mice; Picolinate

Indexed keywords

CHROMIUM; CHROMIUM PICOLINATE; GLYCOSYLATED HEMOGLOBIN; HYDROXYL RADICAL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DIET SUPPLEMENTATION; DNA DAMAGE; DRUG SAFETY; FEMALE; FETUS; FETUS DEVELOPMENT; FETUS OUTCOME; FETUS WEIGHT; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OXIDATIVE STRESS; PREGNANCY; PREGNANCY DIABETES MELLITUS; PRENATAL EXPOSURE; PRIORITY JOURNAL; SKELETON MALFORMATION; TREATMENT PLANNING; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANIMALS; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYONIC DEVELOPMENT; FEMALE; FETAL DEVELOPMENT; MATERNAL EXPOSURE; MICE; MICE, INBRED STRAINS; ORGANOMETALLIC COMPOUNDS; PICOLINIC ACIDS; PREGNANCY; TERATOGENS;

MUS; RATTUS;

EID: 39849089793     PISSN: 15429733     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrb.20140     Document Type: Article

References (40)

1. Abraham A, Brooks B, Eylath U. 1992. The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin dependent diabetes. Metabolism 41:768-771.
2. Anderson R, Polansky M, Bryden N, Roginski E, Mertz W, Glinsmann W. 1983. Chromium supplementation of human subjects: effects on glucose, insulin, and lipid parameters. Metabolism 32:894-899.
3. Anderson R, Polansky M, Bryden N, Canary J. 1991. Supplemental-chromium effects on glucose, insulin, glucagon, and urinary chromium losses in subjects consuming controlled low-chromium diets. Am J Clin Nutr 54:909-916.
4. Bagchi D, Stohs S, Downs B, Bagchi M, Preuss H. 2002. Cytotoxicity and oxidative mechanisms of different forms of chromium. Toxicology 180:5-22.
5. Bailey M, Boohaker J, Sawyer R, Behling J, Rasco J, Jernigan J, Hood R, Vincent J. 2006. Exposure of pregnant mice to chromium picolinate results in skeletal defects in their offspring. Birth Defects Res B 77:244-249.
6. 2O (Hpic = ‴ picolinic acid). Polyhedron 18:2891-2897.
7. 3-oxo-m-hexapropionatotrichromium(III) in rats. Biol Trace Elem Res 97:1-11.
8. + increases insulin sensitivity and improves blood plasma variables in healthy and type 2 diabetic rats. J Biol Inorg Chem 10:119-130.
9. Coryell V, Stearns D. 2006. Molecular analysis of hprt mutations induced by chromium picolinate in CHO AA8 cells. Mutat Res 610:114-123.
10. Davis C, Vincent J. 1997. Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry 36:4382-4385.
11. Davis C, Royer A, Vincent J. 1997. Synthetic multi-nuclear chromium assembly activates insulin receptor kinase activity: functional model for low-molecular-weight chromium-binding substance. Inorg Chem 36:5316-5320.
12. Dillon C, Lay P, Bonin A, Cholewa M, Legge G. 2000. Permeability, cytotoxicity, and genotoxicity of Cr(III) complexes and some Cr(IV) analogues in V79 Chinese hamster lung cells. Chem Res Toxicol 13:742-748.
13. Earnshaw A, Figgis B, Lewis J. 1966. Chemistry of polynuclear compounds. Part IV. Magnetic properties of trimeric chromium and iron compounds. J Chem Soc (A):1656-1663.
14. Glinsmann W, Mertz W. 1966. Effects of trivalent chromium on glucose tolerance. Metabolism 15:510-519.
15. Gudi R, Slesinski R, Clarke J, San R. 2005. Chromium picolinate does not produce chromium damage in CHO cells. Mutat Res 587:140-146.
16. Gurson C, Saner G. 1971. Effect of chromium on glucose utilization in marasmic protein-calorie nutrition. Am J Clin Nutr 24:1313-1319.
17. Hepburn D, Vincent J. 2003a. Tissue and subcellular distribution of chromium picolinate with time after entering the bloodstream. J Bioinorg Chem 94:84-93.
18. Hopkins LJ, Ransome-Kuti O, Majaj A. 1968. Improvement of impaired carbogydrate metabolism by chromium(III) in sensitizing infants. Am J Clin Nutr 21:203-211.
19. Jovanovic L, Gutierrez M, Peterson C. 1999. Chromium supplementation for women with gestational diabetes mellitus. J Trace Elements Exp Nutr 12:91-97.
20. Levina A, Barr-David G, Codd R, Lay P, Dixon N, Hammershoi A, Hendry P. 1999. In vitro plasmid DNA cleavage by chromium(V) and (IV) 2-hydroxycarboxylato complexes. Chem Res Toxicol 12:371-381.
21. Morris B, MacNeil S, Fraser R, Gray T. 1995. Increased urine chromium excretion in normal pregnancy. Clinical Chemistry 41:1544-1545.
22. O'Flaherty E, Kerger B, Hays S, Paustenbach D. 2001. A physiologically based model for the ingestion of chromium(III) and chromium(VI) by humans. Toxicol Sci 60:196-213.
23. Press R, Gellar J, Evans G. 1990. The effects of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects. West J Med 152:41-45.
24. Shinde U, Sharma G, Xu Y, Dhalla N, Goyal R. 2004. Insulin sensitizing action of chromium picolinate in various experimental models of diabetes mellitus. J Trace Elements Med Biol 18:23-32.
25. Slesinski R, Clarke J, San R, Gudi R. 2005. Lack of mutagenicity of chromium picolinate in the hypoxanthine phosphoribosyltransferase gene mutation assay in Chinese hamster ovary cells. Mutat Res 585:86-95.
26. Speetjens J, Collins R, Vincent J, Woski S. 1999a. The nutritional supplement chromium(III) tris(picolinate) cleaves DNA. Chem Res Toxicol 12:483-487.
27. + do not cleave DNA under physiologically-relevant conditions. Polyhedron 18:2617-2624.
28. Stearns D, J Wise S, Patierno S, Wetterhahn K. 1995a. Chromium(III) picolinate produces chromosome damage in Chinese hamster ovary cells. FASEB J 9:1643-1648.
29. Stearns D, Beibruno J, Wetterhahn K. 1995b. A prediction of chromium(III) accumulation in humans from chromium dietary supplements. FASEB J 9:1650-1657.
30. Stearns D, Silveira S, Wolf K, Luke A. 2002. Chromium(III) tris (picolinate) is mutagenic at the hypoxanthine (guanine) phosphoribotransferase locus in Chinese hamster ovary cells. Mutat Res 513:135-142.
31. Sugden K, Wetterhahn K. 1997. Direct and hydrogen peroxide-induced chromium(V) oxidation of deoxyribose in single-stranded and double-stranded calf thymus DNA. Chem Res Toxicol 10:1397-1406.
32. + decreases plasma cholesterol and triglycerides in rats: towards chromium-containing therapeutics. J Biol Inorg Chem 4:838-845.
33. + decreases plasma insulin, cholesterol, and triglycerides in healthy and type II diabetic rats but not type I diabetic rats. J Biol Inorg Chem 7:852-862.
34. 2O, MeOH, py). Inorg Chem 32:3408-3411.
35. Vincent J. 2000a. Elucidating a biological role for chromium at a molecular level. Accounts Chem Res 33:503-510.
36. Vincent J. 2000b. Quest for the molecular mechanism of chromium action and its relationship to diabetes. Nutr Rev 58:67-72.
37. Vincent J. 2001. The bioinorganic chemistry of chromium(III). Polyhedron 20:1-26.
38. Vincent J. 2004. Recent advances in the nutritional biochemistry of trivalent chromium. Proc Nutr Soc 63:41-47.
39. Webb G, Byrd R. 1994. Simultaneous differential staining of cartilage and bone without glacial acetic acid. Biotech Histochem 69:181-185.
40. Whittaker P, San R, Clarke J, Seifried H, Dunkel V. 2005. Mutagenicity of chromium picolinate and its components in Salmonella typhimurium and L5178Y mouse lymphoma cells. Food Chem Toxicol 43:1619-1625.